Noninvasive Monitoring of Programmed Death-Ligand 2 Expression with Positron Emission Tomography using ⁶⁸Ga-labeled Peptide Antagonist in Preclinical and Exploratory Human Studies.

ABSTRACT: While the expression of programmed death ligand-1 (PD-L1) is associated with response to immune therapy, PD-L1-negative patients may still benefit from immune treatment. Programmed death ligand-2 (PD-L2), another crucial immune checkpoint molecule interacting with PD-1, correlates with the efficacy of various tumor immune therapies. This study investigates the expression of PD-L2 in non-small cell lung cancer (NSCLC) patients following anti-PD-1 therapy and its predictive value for clinical survival outcomes. Additionally, we explore the noninvasive, real-time, and dynamic quantitative analysis potential of PD-L2 positron emission tomography (PET) imaging in transplanted tumors. We utilized [⁶⁸Ga]Ga-labeled peptide HN11-1 for PD-L2 PET imaging. The results indicate a higher resp

SUBMITTER: Zhao Y 

PROVIDER: S-EPMC11528066 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature